Investigation of the ongoing pulmonary defects with perfusion-single photon emission computed tomography/computed tomography in patients under anticoagulant therapy for coronavirus disease 2019-induced pulmonary embolism.


Journal

Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017

Informations de publication

Date de publication:
01 09 2022
Historique:
pubmed: 11 8 2022
medline: 13 8 2022
entrez: 10 8 2022
Statut: ppublish

Résumé

It was aimed to reveal the continuing perfusion defect rates in patients with a diagnosis of pulmonary embolism (PE) due to COVID-19 who have completed the third month of anticoagulant therapy but whose symptoms or laboratory elevations continue. Patients with COVID-19 who were diagnosed with PE by Q-SPECT-CT between 1 September 2020 and 1 November 2021, who underwent control Q-SPECT/CT were included in the study. Demographic characteristics, laboratory findings, and first and second Q-SPECT/CT evaluation results of the patients were recorded. It was observed that the pulmonary defect continued in Q-SPECT/CT in the third month of anticoagulant treatment in 58.3% of the patients diagnosed with PE due to COVID-19, and new defects developed in 6.3%. The persistence rate of segment defects was higher than that of subsegment defects. It was observed that the defects persisted more frequently in patients with a history of hospitalization due to COVID-19. Perfusion defects may still be present in patients diagnosed with PE due to COVID-19 in the presence of persistent dyspnea/chest pain/D-dimer elevation after 3 months of treatment. Perfusion defect persistence rates are higher in defects more proximal to the subsegment level and in people with severe COVID-19, and extended treatment should be considered in these patients.

Identifiants

pubmed: 35947122
doi: 10.1097/MNM.0000000000001595
pii: 00006231-202209000-00003
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

978-986

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Références

Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? Lancet 2020; 395:1758–1759.
Kumar N, Xie K, Mar W, Anderson TM, Carney B, Mehta N, et al. Software-based hybrid perfusion SPECT/CT provides diagnostic accuracy when other pulmonary embolism imaging is indeterminate. Nucl Med Mol Imaging 2015; 49:303–311.
Phillips JJ, Straiton J, Staff RT. Planar and SPECT ventilation/perfusion imaging and computed tomography for the diagnosis of pulmonary embolism: a systematic review and meta-analysis of the literature, and cost and dose comparison. Eur J Radiol 2015; 84:1392–1400.
Wang M, Wu D, Ma R, Zhang Z, Zhang H, Han K, et al. Comparison of V/Q SPECT and CT angiography for the diagnosis of chronic thromboembolic pulmonary hypertension. Radiology 2020; 296:420–429.
Thanuja M, Maimanah M, Sara U. Diagnosis of pulmonary embolism: a comparison between ventilation/perfusion SPECT/CT and perfusion-only SPECT/CT. Med J Malaysia 2020; 75:490–493.
Mahaletchumy T, Muhamad M, Mohammad Kazmin NE, Kori N, Periyasamy P. Pulmonary embolism in an asymptomatic COVID-19 patient detected on ventilation/perfusion SPECT/CT. Clin Nucl Med 2021; 46:e360–e362.
Ozturk BC, Atahan E, Gencer A, Harbiyeli DO, Karabul E, Mazican N, et al. Correction to: investigation of perfusion defects by Q-SPECT/CT in patients with mild-to-moderate course of COVID-19 and low clinical probability for pulmonary embolism. Ann Nucl Med 2021; 35:1126.
Lu Y, Macapinlac HA. Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic. Eur J Nucl Med Mol Imaging 2020; 47:2064–2065.
Burger IA, Niemann T, Patriki D, Fontana F, Beer JH. Is there a role for lung perfusion [99mTc]-MAA SPECT/CT to rule out pulmonary embolism in COVID-19 patients with contraindications for iodine contrast? Eur J Nucl Med Mol Imaging 2020; 47:2062–2063.
Vöö S, Neriman D, Henry M, Kayani I. Perfusion-ventilation imaging in an era of COVID-19. Nucl Med Commun 2020; 41:597–598.
Vöö S, Dizdarevic S. Single photon emission computed tomography lung perfusion imaging during the COVID-19 pandemic: does nuclear medicine need to reconsider its guidelines? Nucl Med Commun 2020; 41:991–993.
Burger IA, Niemann T, Patriki D, Fontana F, Beer JH. Lung perfusion [99mTc]-MAA SPECT/CT to rule out pulmonary embolism in COVID-19 patients with contraindications for iodine contrast. Eur J Nucl Med Mol Imaging 2020; 47:2209–2210.
Lu Y, Lorenzoni A, Fox JJ, Rademaker J, Vander Els N, Grewal RK, et al. Noncontrast perfusion single-photon emission CT/CT scanning: a new test for the expedited, high-accuracy diagnosis of acute pulmonary embolism. Chest 2014; 145:1079–1088.
Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170:1710–1716.
Agrawal V, Kim ESH. Risk of recurrent venous thromboembolism after an initial episode: risk stratification and implications for long-term treatment. Curr Cardiol Rep 2019; 21:24.
Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Braekkan SK. Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 2017; 15:295–303.
Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al.; COMMAND VTE Registry Investigators. Anticoagulation therapy for venous thromboembolism in the real world - from the COMMAND VTE registry. Circ J 2018; 82:1262–1270.
Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv 2018; 2:788–796.
Kearon C, Spencer FA, O’Keeffe D, Parpia S, Schulman S, Baglin T, et al.; D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015; 162:27–34.
Kearon C, Parpia S, Spencer FA, Schulman S, Stevens SM, Shah V, et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; a cohort study. J Thromb Haemost 2019; 17:1144–1152.
van Es J, Cheung YW, van Es N, Klok FA, Dronkers CEA, Ten Wolde M, et al. Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. Thromb Res 2020; 187:125–130.
Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 2020; 158:1143–1163.
Prandoni P, Barbar S, Milan M, Vedovetto V, Pesavento R. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. Eur J Intern Med 2014; 25:25–30.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149:315–352.
Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603–605.
Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology 2020; 296:E186–E188.
Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145–147.
Mestre-Gómez B, Lorente-Ramos RM, Rogado J, Franco-Moreno A, Obispo B, Salazar-Chiriboga D, et al.; Infanta Leonor Thrombosis Research Group. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis 2021; 51:40–46.
Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med 2021; 9:107–116.

Auteurs

Buket Caliskaner Ozturk (B)

Departments of Pulmonary Diseases.

Ersan Atahan (E)

Departments of Pulmonary Diseases.

Ali Kibar (A)

Nuclear Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Sait Sager (S)

Nuclear Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Sermin Borekci (S)

Departments of Pulmonary Diseases.

Bilun Gemicioglu (B)

Departments of Pulmonary Diseases.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH